Patents by Inventor Vincent D. Romeo
Vincent D. Romeo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040242625Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: April 21, 2004Publication date: December 2, 2004Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20040242624Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: April 21, 2004Publication date: December 2, 2004Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20040242626Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: April 21, 2004Publication date: December 2, 2004Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20040204441Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: April 21, 2004Publication date: October 14, 2004Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20040101484Abstract: Intranasal delivery compositions and methods for the delivery of dopamine receptor agonists are provided which are effective for the treatment14 of sexual dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal, in particular adverse nasal effects. Nasally administered compositions for treating sexual dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: November 5, 2003Publication date: May 27, 2004Inventors: Charanjit R. Behl, Vincent D. Romeo, Raja G. Achari, Shamin Ahmed, Jorge C. Demeireles, Tianquing Liu, Anthony P. Sileno
-
Patent number: 6740660Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: GrantFiled: January 31, 2002Date of Patent: May 25, 2004Assignee: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Patent number: 6677346Abstract: The present invention relates to a pharmaceutical formulation for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0. Such formulations provide enhanced absorption of morphine or pharmaceutically acceptable salts thereof. In one embodiment, the present invention provides a method for eliciting an analgesic or anesthetic response in a mammal which includes nasally administering a therapeutically effective amount of morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0.Type: GrantFiled: June 15, 2000Date of Patent: January 13, 2004Assignee: Nastech Pharmaceutical Company Inc.Inventors: Raja G. Achari, Charanjit R. Behl, Jorge C. deMeireles, Ramneik Dua, Vincent D. Romeo, Anthony P. Sileno
-
Patent number: 6599883Abstract: The present invention is a method and pharmaceutical composition for prevention and/or treatment of upper respiratory infections including otitis media by nasal administration of xylitol.Type: GrantFiled: October 29, 1999Date of Patent: July 29, 2003Assignee: Nastech Pharmaceutical Company, Inc.Inventors: Vincent D. Romeo, Charanjit R. Behl
-
Publication number: 20020193397Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: January 31, 2002Publication date: December 19, 2002Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20020165249Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: January 31, 2002Publication date: November 7, 2002Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20020161017Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: January 31, 2002Publication date: October 31, 2002Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Patent number: 6451848Abstract: The present invention relates to a pharmaceutical composition which includes morphine gluconate or chemical equivalent thereof. In one embodiment, the present invention includes a method of making morphine gluconate or chemical equivalent thereof by mixing morphine sulfate with sodium gluconate. The present invention also includes a method for eliciting an analgesic or anesthetic response in a mammal which includes administering a therapeutically effective amount of a pharmaceutical composition including morphine gluconate or chemical equivalent thereof.Type: GrantFiled: October 19, 2000Date of Patent: September 17, 2002Assignee: Nastech Pharmaceutical Company, Inc.Inventors: Charanjit R. Behl, Vincent D. Romeo, Anthony P. Sileno
-
Patent number: 6436950Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: GrantFiled: June 16, 1999Date of Patent: August 20, 2002Assignee: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20020002175Abstract: Intranasal delivery compositions and methods for the delivery of dopamine receptor agonists are provided which are effective for the treatment14 of sexual dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal, in particular adverse nasal effects. Nasally administered compositions for treating sexual dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: June 11, 2001Publication date: January 3, 2002Inventors: Charanjit Behl, Vincent D. Romeo, Raja Achari, Shamin Ahmed, Jorge deMeireles, Tianquing Liu, Anthony Sileno
-
Patent number: 6225343Abstract: The present invention relates to a pharmaceutical composition which includes morphine gluconate or chemical equivalent thereof. In one embodiment, the present invention includes a method of making morphine gluconate or chemical equivalent thereof by mixing morphine sulfate with sodium gluconate. The present invention also includes a method for eliciting an analgesic or anesthetic response in a mammal which includes administering a therapeutically effective amount of a pharmaceutical composition including morphine gluconate or chemical equivalent thereof.Type: GrantFiled: June 16, 1999Date of Patent: May 1, 2001Assignee: Nastech Pharmaceutical Company, Inc.Inventors: Charanjit R. Behl, Vincent D. Romeo, Anthony P. Sileno
-
Patent number: 5874450Abstract: Intranasal dosage units for promoting sleep in a mammal are disclosed. The dosage units are in the form of an aqueous buffered solution having a pH greater than 7.0, a sleep-promoting amount of Doxylamine, and an effective amount of an anionic surfactant. The anionic surfactant amount is an amount effective to provide a peak plasma concentration of Doxylamine to be reached within 30 minutes of administering the dosage unit to the nasal mucosa of a mammal. The dosage units are particularly suitable for administration to humans.Type: GrantFiled: September 29, 1997Date of Patent: February 23, 1999Assignee: Nastech Pharmaceutical Company, Inc.Inventors: Charanjit R. Behl, Jorge C. DeMeireles, Harish K. Pimplaskar, Vincent D. Romeo, Anthony P. Sileno, Wei J. Xia
-
Patent number: 5770618Abstract: A method is disclosed for increasing the solubility of clemastine through the use of organic acid or its salts as a solubilizing agent. Particularly useful as solubilizing agents are salts of carboxylic acids, such as fumarate, maleate and citrate. Pharmaceutical compositions containing clemastine, and organic acids or its salts as solubilizing agents, are also disclosed.Type: GrantFiled: November 13, 1996Date of Patent: June 23, 1998Assignee: Nastech Pharmaceutical Company, Inc.Inventors: Charanjit R. Behl, Jorge C. deMeireles, Vincent D. Romeo, Anthony P. Sileno, Harish K. Pimplaskar, Wei J. Xia